Michael Jeng
Publication Details
-
Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis.
Pediatr Blood Cancer. 2013; (6): E19-22
Pediatric patients with refractory multisystem Langerhans cell histiocytosis (LCH) have a poor prognosis despite aggressive chemotherapy. Salvage therapy with cytarabine and cladribine has shown promise as an effective treatment but is associated with significant toxicity. A previous report described two patients with refractory LCH who had a rapid response to single-agent clofarabine with minimal toxicity. In this report, we describe four children with refractory, risk-organ-positive LCH who were treated with clofarabine and provide follow-up for the two previously reported cases. The results support development of a formal trial evaluating clofarabine as front-line salvage for refractory LCH. Pediatr Blood Cancer 2013; 60: E19-E22. © 2012 Wiley Periodicals, Inc.
Help